MSN Pushes for Rehearing on Revival of Novartis’ Entresto Patent

MSN Laboratories Pvt. Ltd. urged the Federal Circuit to reconsider a three-judge panel’s January ruling that revived a patent for Novartis AG’s blockbuster heart-disease drug Entresto.

The Jan. 10 decision—which prompted a flurry of filings in several venues over the launch timing for MSN’s generic Entresto—contradicted established patent law principles, according to a petition seeking panel or en banc rehearing filed Monday in the US Court of Appeals for the Federal Circuit. The ruling also failed to take into account that the valsartan-sacubitril complexes were undisputedly unknown at the time of invention, it said.

• “The panel’s decision ignored the ...